Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Peter Singleton who wrote (3583)	1/11/1998 4:18:00 PM
From: JOHN W.	Read Replies (1) of 6136

PW recent comments (1/6): "AGPH is rated buy 1 and continues to be our Analyst Best Call for 1998. In our opinion, the stock decline in December was an overreaction to the termination of the Rpche cancer collaboration and of the Thymitaq program and was compounded by the year-end tax loss selling. we believe at current levels, the stock offers an excellent opportunity for near term investment. Viracept, the company's first commercial product, is at a current annual run rate of over $300 million, an unprecedented market launch for any biotechnology product. We believe Viracept will continue to post robust sales for the next few years as additional clinical data is released on the drug. We are anticipating a better than expected earnings report for fiscal Q2 98 to be released during the week of Jan 10th. Our 12 month target is $65-70 based on our fiscal 1999 (ended June) EPS estimate of $3.43 discounted at 25-30% with a 30 multiple. The stock is currently trading at a P/E multiple of only 22x our calendar 1999 EPS estimate of $1.56.""

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next